SARS-CoV-2 (COVID-19) in patients with some degree of immunosuppression.
Cancer
Coronavirus
Cáncer
Diseases of the nervous system
Enfermedades del sistema nervioso
Enfermedades reumáticas
Human immunodeficiency virus
Immunosuppression
Inmunosupresión
Rheumatic diseases
Transplantation
Trasplante
Virus de la inmunodeficiencia humana
Journal
Reumatologia clinica
ISSN: 2173-5743
Titre abrégé: Reumatol Clin (Engl Ed)
Pays: Spain
ID NLM: 101717526
Informations de publication
Date de publication:
Historique:
received:
08
05
2020
accepted:
06
08
2020
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
10
8
2021
Statut:
ppublish
Résumé
It is not clear whether patients with some degree of immunosuppression have worse outcomes in SARS-CoV-2 infection, compared to healthy people. To carry out a narrative review of the information available on infection by SARS-CoV-2 in immunosuppressed patients, especially patients with cancer, transplanted, neurological diseases, primary and secondary immunodeficiencies. Patients with cancer and recent cancer treatment (chemotherapy or surgery) and SARS-CoV-2 infection have a higher risk of worse outcomes. In transplant patients (renal, cardiac and hepatic), with neurological pathologies (multiple sclerosis (MS), neuromyelitis optica (NMODS), myasthenia gravis (MG)), primary immunodeficiencies and infection with human immunodeficiency virus (HIV) in association with immunosuppressants, studies have shown no tendency for worse outcomes. Given the little evidence we have so far, the behaviour of SARS-CoV-2 infection in immunosuppressed patients is unclear, but current studies have not shown worse outcomes, except for patients with cancer.
Sections du résumé
BACKGROUND
BACKGROUND
It is not clear whether patients with some degree of immunosuppression have worse outcomes in SARS-CoV-2 infection, compared to healthy people.
OBJECTIVE
OBJECTIVE
To carry out a narrative review of the information available on infection by SARS-CoV-2 in immunosuppressed patients, especially patients with cancer, transplanted, neurological diseases, primary and secondary immunodeficiencies.
RESULTS
RESULTS
Patients with cancer and recent cancer treatment (chemotherapy or surgery) and SARS-CoV-2 infection have a higher risk of worse outcomes. In transplant patients (renal, cardiac and hepatic), with neurological pathologies (multiple sclerosis (MS), neuromyelitis optica (NMODS), myasthenia gravis (MG)), primary immunodeficiencies and infection with human immunodeficiency virus (HIV) in association with immunosuppressants, studies have shown no tendency for worse outcomes.
CONCLUSION
CONCLUSIONS
Given the little evidence we have so far, the behaviour of SARS-CoV-2 infection in immunosuppressed patients is unclear, but current studies have not shown worse outcomes, except for patients with cancer.
Identifiants
pubmed: 34301385
pii: S2173-5743(20)30129-5
doi: 10.1016/j.reumae.2020.08.001
pmc: PMC7566826
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
408-419Informations de copyright
Copyright © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.
Références
Neurology. 2020 Jun 2;94(22):949-952
pubmed: 32241953
Mil Med Res. 2020 Mar 13;7(1):11
pubmed: 32169119
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Lancet Infect Dis. 2018 Aug;18(8):e217-e227
pubmed: 29680581
Aging (Albany NY). 2020 Apr 8;12(7):6049-6057
pubmed: 32267833
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Mult Scler Relat Disord. 2020 Jul;42:102120
pubmed: 32315980
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
J Med Virol. 2020 Oct;92(10):1777-1778
pubmed: 32293709
Clin Liver Dis (Hoboken). 2016 Aug 29;8(2):34-38
pubmed: 31041060
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Transpl Infect Dis. 2020 Oct;22(5):e13382
pubmed: 32583620
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Blood. 2020 Aug 6;136(6):755-759
pubmed: 32573724
Cancer. 2020 Jul 15;126(14):3171-3173
pubmed: 32584455
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
JAMA. 2020 Apr 21;323(15):1499-1500
pubmed: 32159735
Neurology. 2020 Jul 14;95(2):77-84
pubmed: 32345728
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Neurol Neuroimmunol Neuroinflamm. 2020 Jun 4;7(5):
pubmed: 32503092
Diabetes Metab Res Rev. 2020 Mar 31;:e3319
pubmed: 32233013
Indian J Pediatr. 2020 Apr;87(4):281-286
pubmed: 32166607
PLoS Med. 2006 Sep;3(9):e343
pubmed: 16968120
Am J Transplant. 2020 Jul;20(7):1941-1943
pubmed: 32233067
Dermatol Ther. 2020 Jul;33(4):e13509
pubmed: 32367558
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
Clin Res Cardiol. 2020 May;109(5):531-538
pubmed: 32161990
Hepatology. 2020 Oct;72(4):1491-1493
pubmed: 32220017
BMJ. 2020 Apr 28;369:m1626
pubmed: 32345591
Am J Transplant. 2020 Nov;20(11):3173-3181
pubmed: 32529737
Mult Scler Relat Disord. 2020 Sep;44:102310
pubmed: 32590314
Diagnostics (Basel). 2020 Apr 05;10(4):
pubmed: 32260471
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Eur J Med Chem. 2020 Sep 1;201:112527
pubmed: 32563812
Lancet. 2020 Mar 7;395(10226):809-815
pubmed: 32151335
Chin Med J (Engl). 2020 May 5;133(9):1015-1024
pubmed: 32004165
Pathogens. 2020 Mar 04;9(3):
pubmed: 32143502
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Clin Transplant. 2020 Oct;34(10):e14027
pubmed: 32589760
Liver Transpl. 2020 Jun;26(6):832-834
pubmed: 32196933
Lancet HIV. 2020 May;7(5):e314-e316
pubmed: 32304642
Muscle Nerve. 2020 Aug;62(2):254-258
pubmed: 32392389
Pediatr Infect Dis J. 2007 Jan;26(1):68-74
pubmed: 17195709
Lancet HIV. 2020 May;7(5):e308-e309
pubmed: 32272084
Lancet Infect Dis. 2020 Jul;20(7):793-802
pubmed: 32247326
J Allergy Clin Immunol Pract. 2020 Jun;8(6):1894-1899.e2
pubmed: 32278865
World J Pediatr. 2020 Jun;16(3):240-246
pubmed: 32026148
Ann Rheum Dis. 2020 May;79(5):667-668
pubmed: 32241793
Lancet. 2020 May 22;:
pubmed: 32450107
Ann Intern Med. 2021 Apr;174(4):581-582
pubmed: 33872541
Obesity (Silver Spring). 2020 May;28(5):847
pubmed: 32237212
J Med Virol. 2020 Jun;92(6):529-530
pubmed: 32160316
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Rev Neurol. 2020 May 1;70(9):329-340
pubmed: 32329046
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
JCO Glob Oncol. 2020 Apr;6:557-559
pubmed: 32250659
Autoimmun Rev. 2020 Jul;19(7):102554
pubmed: 32380316
Int J Antimicrob Agents. 2020 Apr;55(4):105932
pubmed: 32145363
J Med Virol. 2020 Oct;92(10):1915-1921
pubmed: 32293753
Exp Biol Med (Maywood). 2009 Oct;234(10):1117-27
pubmed: 19546349
Nat Rev Neurol. 2016 Apr;12(4):217-33
pubmed: 26943779
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Clin Infect Dis. 2020 Jul 28;71(15):841-843
pubmed: 32047895
Am J Transplant. 2020 Jul;20(7):1875-1878
pubmed: 32198834
J Neurol Sci. 2020 Jul 15;414:116888
pubmed: 32413767
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
J Clin Virol. 2020 Jun;127:104354
pubmed: 32305882
J Neurol Sci. 2020 May 15;412:116803
pubmed: 32247193
Lancet. 2020 Jun 13;395(10240):1820
pubmed: 32511943
J Neuromuscul Dis. 2020;7(3):361-364
pubmed: 32508329
Ther Drug Monit. 2020 Jun;42(3):360-368
pubmed: 32304488
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Emerg Microbes Infect. 2020 Dec;9(1):386-389
pubmed: 32065057
Am J Transplant. 2020 Jul;20(7):1896-1901
pubmed: 32337790
Transpl Int. 2020 Sep;33(9):1040-1045
pubmed: 32357275
Mult Scler. 2017 Oct;23(11):1506-1516
pubmed: 28273769
Mult Scler Relat Disord. 2020 Apr;39:102073
pubmed: 32334820
ESMO Open. 2020 Mar;5(2):
pubmed: 32229501
JCO Glob Oncol. 2020 Apr;6:569-570
pubmed: 32282234